Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)
China · Delayed Price · Currency is CNY 53.09
-1.59 (-2.91%)
Apr 28, 2026, 3:04 PM CST
SHE:002294 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 676.45 | 651.5 | 601.57 | 580.07 | 637.09 | 533.73 |
Depreciation & Amortization | 402.29 | 402.29 | 376.23 | 345.61 | 320.16 | 304.27 |
Other Amortization | 34.4 | 34.4 | 32.72 | 29.83 | 28.87 | 20.16 |
Loss (Gain) From Sale of Assets | 3.03 | 3.03 | 0.15 | 0.48 | 0.18 | 1.3 |
Asset Writedown & Restructuring Costs | 151.86 | 151.86 | 159.64 | 52.5 | 50.67 | 131.6 |
Loss (Gain) From Sale of Investments | -76.08 | -76.08 | -47.95 | -20.21 | -44.14 | -134.24 |
Provision & Write-off of Bad Debts | 4.45 | 4.45 | 5.52 | 2.49 | 3 | 0.44 |
Other Operating Activities | -41.63 | -32.57 | 26.96 | 25.8 | 11.66 | 30.32 |
Change in Accounts Receivable | -219.16 | -219.16 | -57.58 | 3.96 | -89.42 | 69.97 |
Change in Inventory | -47.74 | -47.74 | -56.4 | 51.23 | -114.11 | -46.53 |
Change in Accounts Payable | 222.34 | 222.34 | 178.5 | -245.1 | 41.69 | 277.54 |
Change in Other Net Operating Assets | 27.49 | 27.49 | 22.8 | 25.91 | 104.38 | - |
Operating Cash Flow | 1,068 | 1,052 | 1,186 | 839.44 | 970.8 | 1,185 |
Operating Cash Flow Growth | -5.08% | -11.28% | 41.32% | -13.53% | -18.07% | -13.78% |
Capital Expenditures | -1,035 | -974.1 | -624.81 | -671 | -598.96 | -482.5 |
Sale of Property, Plant & Equipment | 1.18 | 1.17 | 0.64 | 0.58 | 0.59 | 1.59 |
Cash Acquisitions | -44.17 | -44.17 | - | - | - | - |
Investment in Securities | 112.48 | 206.72 | -946.99 | -730.75 | -682.06 | 93.53 |
Other Investing Activities | 115.75 | 65.56 | 45.61 | 30.35 | 7.12 | 17.73 |
Investing Cash Flow | -850.16 | -744.82 | -1,526 | -1,371 | -1,273 | -369.65 |
Short-Term Debt Issued | - | - | - | 223.73 | 596.83 | 303.9 |
Long-Term Debt Issued | - | 311.09 | 119.3 | - | - | - |
Total Debt Issued | 310.07 | 311.09 | 119.3 | 223.73 | 596.83 | 303.9 |
Short-Term Debt Repaid | - | -187 | -39.84 | -358.63 | -183.6 | -639.52 |
Long-Term Debt Repaid | - | -13.99 | -14.28 | -16.67 | -10.82 | -13.36 |
Total Debt Repaid | -262.19 | -200.99 | -54.12 | -375.3 | -194.42 | -652.87 |
Net Debt Issued (Repaid) | 47.88 | 110.1 | 65.18 | -151.56 | 402.41 | -348.97 |
Issuance of Common Stock | - | - | 601.92 | - | - | 2,331 |
Repurchase of Common Stock | - | - | - | - | -274.31 | -327.86 |
Common Dividends Paid | -559.75 | -558.22 | -546.04 | -549.37 | -441.2 | -15.54 |
Other Financing Activities | -24.8 | -5.74 | 0.77 | -4.57 | -88.41 | -90.45 |
Financing Cash Flow | -536.67 | -453.86 | 121.84 | -705.5 | -401.5 | 1,548 |
Foreign Exchange Rate Adjustments | -19.35 | -14.1 | 3.95 | 4.07 | 32.96 | -6.77 |
Net Cash Flow | -337.87 | -160.35 | -213.51 | -1,233 | -671.04 | 2,357 |
Free Cash Flow | 32.93 | 78.34 | 561.45 | 168.44 | 371.84 | 702.48 |
Free Cash Flow Growth | -93.03% | -86.05% | 233.31% | -54.70% | -47.07% | -4.01% |
Free Cash Flow Margin | 0.73% | 1.80% | 13.99% | 5.00% | 10.68% | 22.97% |
Free Cash Flow Per Share | 0.03 | 0.07 | 0.50 | 0.15 | 0.34 | 0.66 |
Cash Income Tax Paid | 500.07 | 465.32 | 455.26 | 406.42 | 404.25 | 324.11 |
Levered Free Cash Flow | 77.72 | 322.74 | 371.24 | -508.39 | 494.8 | 240.9 |
Unlevered Free Cash Flow | 91.16 | 336.3 | 381.35 | -497.53 | 502.64 | 247.48 |
Change in Working Capital | -86.45 | -86.45 | 31.42 | -177.12 | -36.68 | 297.41 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.